192 related articles for article (PubMed ID: 2725474)
1. Tetrahydroaminoacridine and other allosteric antagonists of hippocampal M1 muscarine receptors.
Potter LT; Ferrendelli CA; Hanchett HE; Hollifield MA; Lorenzi MV
Mol Pharmacol; 1989 May; 35(5):652-60. PubMed ID: 2725474
[TBL] [Abstract][Full Text] [Related]
2. Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by tetrahydroaminoacridine.
Flynn DD; Mash DC
J Pharmacol Exp Ther; 1989 Aug; 250(2):573-81. PubMed ID: 2760841
[TBL] [Abstract][Full Text] [Related]
3. Effects of tetrahydroaminoacridine on M1 and M2 muscarine receptors.
Pearce BD; Potter LT
Neurosci Lett; 1988 Jun; 88(3):281-5. PubMed ID: 3386874
[TBL] [Abstract][Full Text] [Related]
4. Interactions of cocaine with primary and secondary recognition sites on muscarinic receptors.
Flynn DD; Vaishnav AA; Mash DC
Mol Pharmacol; 1992 Apr; 41(4):736-42. PubMed ID: 1569924
[TBL] [Abstract][Full Text] [Related]
5. Characterization of muscarinic M4 binding sites in rabbit lung, chicken heart, and NG108-15 cells.
Lazareno S; Buckley NJ; Roberts FF
Mol Pharmacol; 1990 Dec; 38(6):805-15. PubMed ID: 2250662
[TBL] [Abstract][Full Text] [Related]
6. Gallamine binding to muscarinic M1 and M2 receptors, studied by inhibition of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to rat brain membranes.
Burke RE
Mol Pharmacol; 1986 Jul; 30(1):58-68. PubMed ID: 3755217
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic discrimination between receptor heterogeneity and allosteric interaction: resultant analysis of gallamine and pirenzepine antagonism of muscarinic responses in rat trachea.
Kenakin T; Boselli C
J Pharmacol Exp Ther; 1989 Sep; 250(3):944-52. PubMed ID: 2778720
[TBL] [Abstract][Full Text] [Related]
8. Muscarinic receptor heterogeneity in rat central nervous system. II. Brain receptors labeled by [3H]oxotremorine-M correspond to heterogeneous M2 receptors with very high affinity for agonists.
Gillard M; Waelbroeck M; Christophe J
Mol Pharmacol; 1987 Jul; 32(1):100-8. PubMed ID: 3600611
[TBL] [Abstract][Full Text] [Related]
9. Subtype selectivity of the positive allosteric action of alcuronium at cloned M1-M5 muscarinic acetylcholine receptors.
Jakubík J; Bacáková L; el-Fakahany EE; Tucek S
J Pharmacol Exp Ther; 1995 Sep; 274(3):1077-83. PubMed ID: 7562472
[TBL] [Abstract][Full Text] [Related]
10. Solubilization with digitonin alters the kinetics of pirenzepine binding to muscarinic receptors from rat forebrain and heart.
Wang JX; Mei L; Yamamura HI; Roeske WR
J Pharmacol Exp Ther; 1987 Sep; 242(3):981-90. PubMed ID: 3116203
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the allosteric interactions of the bisquaternary heptane-1,7-bis(dimethyl-3'-phthalimidopropyl)ammonium bromide at M1 and M2 muscarine receptors.
Christopoulos A; Mitchelson F
Mol Pharmacol; 1994 Jul; 46(1):105-14. PubMed ID: 8058045
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of binding of muscarinic receptor antagonists in rat brain homogenates.
Lee JH; el-Fakahany EE
J Pharmacol Exp Ther; 1985 Jun; 233(3):707-14. PubMed ID: 3839264
[TBL] [Abstract][Full Text] [Related]
13. Allosteric interactions at the m1, m2 and m3 muscarinic receptor subtypes.
Lee NH; el-Fakahany EE
J Pharmacol Exp Ther; 1991 Feb; 256(2):468-79. PubMed ID: 1993991
[TBL] [Abstract][Full Text] [Related]
14. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes.
Watson M; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 1986 May; 237(2):419-27. PubMed ID: 3754581
[TBL] [Abstract][Full Text] [Related]
15. Complex allosteric modulation of cardiac muscarinic receptors by protamine: potential model for putative endogenous ligands.
Hu J; Wang SZ; Forray C; el-Fakahany EE
Mol Pharmacol; 1992 Aug; 42(2):311-21. PubMed ID: 1513329
[TBL] [Abstract][Full Text] [Related]
16. Stabilization of antagonist binding to cardiac muscarinic acetylcholine receptors by gallamine and other neuromuscular blocking drugs.
Nedoma J; Tucek S; Danilov AF; Shelkovnikov SA
J Pharmacol Exp Ther; 1986 Jan; 236(1):219-23. PubMed ID: 3941394
[TBL] [Abstract][Full Text] [Related]
17. Muscarinic responses and binding in a murine neuroblastoma clone (N1E-115). Mediation of separate responses by high affinity and low affinity agonist-receptor conformations.
McKinney M; Stenstrom S; Richelson E
Mol Pharmacol; 1985 Feb; 27(2):223-35. PubMed ID: 2982089
[TBL] [Abstract][Full Text] [Related]
18. Evidence of paired M2 muscarinic receptors.
Potter LT; Ballesteros LA; Bichajian LH; Ferrendelli CA; Fisher A; Hanchett HE; Zhang R
Mol Pharmacol; 1991 Feb; 39(2):211-21. PubMed ID: 1899905
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of binding sites on cardiac muscarinic receptors induced by the neuromuscular blocking agents gallamine and pancuronium.
Dunlap J; Brown JH
Mol Pharmacol; 1983 Jul; 24(1):15-22. PubMed ID: 6135150
[TBL] [Abstract][Full Text] [Related]
20. Influence of ligand choice on the apparent binding profile of gallamine to cardiac muscarinic receptors. Identification of three main types of gallamine-muscarinic receptor interactions.
Lee NH; el-Fakahany EE
J Pharmacol Exp Ther; 1988 Sep; 246(3):829-38. PubMed ID: 3418516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
